Brii Biosciences Limited (BRII-B) disclosed that it repurchased 30,000 ordinary shares on 18 September 2026 via on-market transactions at a uniform price of HK$0.86 per share, representing a total consideration of approximately HK$0.03 million.

Prior to the transaction, the company had 721.93 million issued shares (excluding treasury shares) and 13.02 million treasury shares. Following the repurchase, the issued share count fell marginally by 0.0042% to 721.90 million, while treasury shares increased to 13.05 million. The total outstanding share capital remained unchanged at 734.96 million shares as the repurchased stock has been retained in treasury and not cancelled.

The buyback forms part of the mandate approved on 16 June 2026, which authorises the repurchase of up to 72.19 million shares. Cumulative repurchases under this mandate now stand at 330,000 shares, equivalent to 0.0457% of the issued share base on the mandate date. In line with Hong Kong Stock Exchange rules, Brii Biosciences is subject to a 30-day moratorium—until 18 October 2026—on issuing new shares or disposing of treasury shares following the latest repurchase.